Aclaris Therapeutics, Inc. (ACRS) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 28.24M USD | Liabilities, Current |
| Cash and equivalents | 19.17M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 72.39M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $28.24M | $19.17M | $72.39M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $27.37M | $28.66M | $76.76M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $28.64M | $19.96M | $70.79M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $25.63M | $25.26M | $70.66M | (m) | (m) | (m) |
| 2025-06-30 | $100.00M | $26.84M | $25.40M | $74.40M | $194.00K | (m) | 3.73× |
| 2025-03-31 | $105.56M | $21.51M | $30.36M | $74.96M | $250.00K | (m) | 4.91× |
| 2024-12-31 | $113.91M | $31.60M | $24.57M | $89.02M | $318.00K | (m) | 3.61× |
| 2024-09-30 | $128.06M | $18.82M | $47.65M | $80.07M | $343.00K | (m) | 6.81× |
| 2024-06-30 | $111.42M | $15.68M | $22.83M | $88.26M | $325.00K | (m) | 7.10× |
| 2024-03-31 | $128.54M | $20.08M | $35.84M | $92.33M | $373.00K | (m) | 6.40× |
| 2023-12-31 | $119.40M | $30.95M | $39.88M | $79.23M | $298.00K | (m) | 3.86× |
| 2023-09-30 | $103.40M | $27.32M | $39.04M | $64.01M | $346.00K | (m) | 3.78× |
| 2023-06-30 | $120.21M | $22.83M | $31.15M | $88.63M | $431.00K | (m) | 5.27× |
| 2023-03-31 | $171.49M | $18.26M | $44.72M | $126.08M | $686.00K | (m) | 9.39× |
| 2022-12-31 | $218.06M | $21.94M | $45.28M | $172.29M | $484.00K | (m) | 9.94× |
| 2022-09-30 | $248.66M | $19.79M | $61.65M | $186.41M | $597.00K | (m) | 12.57× |
| 2022-06-30 | $249.24M | $16.22M | $68.26M | $180.34M | $637.00K | (m) | 15.37× |
| 2022-03-31 | $180.25M | $16.73M | $36.34M | $143.28M | $633.00K | (m) | 10.78× |
| 2021-12-31 | $192.04M | $22.93M | $27.35M | $164.06M | $623.00K | (m) | 8.37× |
| 2021-09-30 | $198.69M | $17.84M | $53.60M | $144.28M | $811.00K | (m) | 11.14× |
| 2021-06-30 | $232.61M | $14.92M | $113.45M | $118.23M | $939.00K | (m) | 15.59× |
| 2021-03-31 | $129.11M | $14.51M | $35.27M | $93.03M | $817.00K | (m) | 8.90× |
| 2020-12-31 | $54.90M | $14.87M | $22.06M | $32.07M | $772.00K | (m) | 3.69× |
| 2020-09-30 | $54.36M | $12.79M | $23.64M | $29.83M | $887.00K | (m) | 4.25× |
| 2020-06-30 | (m) | $17.75M | (m) | $35.53M | $775.00K | (m) | (m) |
| 2020-03-31 | (m) | $20.60M | (m) | $25.01M | $933.00K | (m) | (m) |
| 2019-12-31 | (m) | $22.43M | (m) | $39.08M | $704.00K | $0.00 | (m) |
| 2019-09-30 | (m) | $38.99M | (m) | $61.53M | $673.00K | $189.00K | (m) |
| 2019-06-30 | (m) | $42.75M | (m) | $83.86M | $19.37M | $185.00K | (m) |
| 2019-03-31 | (m) | $36.23M | (m) | $102.56M | $15.82M | $856.00K | (m) |
| 2018-12-31 | (m) | $27.34M | (m) | $110.95M | $4.86M | $791.00K | (m) |
| 2018-09-30 | (m) | $22.28M | (m) | $107.68M | $1.03M | $1.04M | (m) |
| 2018-06-30 | (m) | $20.07M | (m) | $118.57M | $2.18M | $1.03M | (m) |
| 2018-03-31 | $187.51M | $13.82M | $54.88M | $132.10M | $529.00K | (m) | 13.56× |
| 2017-12-31 | $194.34M | $12.76M | $20.20M | $173.66M | $481.00K | (m) | 15.23× |
| 2017-09-30 | $228.51M | $9.99M | $60.05M | $167.79M | $658.00K | (m) | 22.87× |
| 2017-06-30 | (m) | $8.37M | $32.71M | $137.79M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $5.64M | $23.68M | $129.74M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $6.22M | $30.17M | $107.05M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $4.59M | $17.80M | $66.25M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $5.51M | $31.82M | $62.20M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $3.73M | $13.13M | $72.11M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $1.55M | $9.85M | $75.02M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $1.90M | $25.42M | $12.99M | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $9.85M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $8.47M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.45M | $10.76M | $5.37M | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $18.89M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $9.59M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $19.04M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |